Generic name:ivosidenib [ EYE-voe-SID-e-nib ]
Drug class:Miscellaneous antineoplastics
What is Tibsovo?
Tibsovo targets a specific gene mutation called IDH1, which can affect your bone marrow. IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia (AML).
Tibsovo is for use only in adults with an IDH1 mutation. Your doctor will test you for this gene.
Tibsovo is used to treat AML after other treatments did not work or stopped working.
Tibsovo is used with or without azacitidine to treat newly-diagnosed AML in adults 75 years and older or who have health problems that prevent the use of certain chemotherapy treatments.
Tibsovo is also used to treat bile duct cancer (cholangiocarcinoma) that has progressed or has spread to other parts of the body (metastatic) after treatment with other medicine.
Warnings
Tibsovo can cause a condition called differentiation syndrome, which affects blood cells and can be fatal if not treated. This condition may occur within 1 days to 3 months after you start taking Tibsovo.
Seek medical help right away if you have symptoms of differentiation syndrome: fever, dizziness, cough, trouble breathing, swelling, rapid weight gain, rash, or decreased urination.
Before taking this medicine
You should not use Tibsovo if you are allergic to ivosidenib.
To make sure you can safely take Tibsovo, tell your doctor if you have ever had:
heart disease;
long QT syndrome (in you or a family member);
nerve ...
